London, United Kingdom, September 11, 2012 --(PR.com
)-- Visiongain forecasts that the overall regenerative medicine market will multiply in size from 2012 to 2022. The regenerative medicine industry is in its infancy; however marketed products have achieved commercial success. Visiongain believes the strength of the regenerative medicine market is its potential to treat a plethora of diseases. Growth of the market will be driven by targeting serious, prevalent disorders such as cancer, cardiovascular disease and diabetes. In these areas, the potential for regenerative medicine technologies is vast, and regulatory and cultural uncertainties about the field will not derail its progress from 2012 to 2022.
Dr Peter Williamson, a pharmaceutical industry analyst in visiongain, said: “Regenerative medicine is a market with huge potential. The key to its future lies in the successful approval and commercialisation of new products. We have already seen commercial success in the tissue engineering sector with products such as Dermagraft and Apligraf. It is important that companies, reimbursement agencies and regulatory authorities learn lessons from these achievements, ultimately guiding efficient developmental processes. In addition, advances in the scientific understanding of cellular mechanisms and how they aid and influence regeneration will strengthen these processes.
“Our study notes that widespread commercialisation will be challenging during the forecast period 2012 to 2022. However, these challenges will be overcome by the maturing market, investment from pharmaceutical companies and the creation of regenerative medicine centres. In addition, there are growing numbers of regenerative medicine start-up companies and research and development (R&D) for regenerative medicine is strong.”
Visiongain’s report shows revenue forecasts to 2022 at overall world market, submarket, product and regional level. It forecasts these world-level submarkets:
• Tissue-engineered products
• Stem cell applications
• Gene therapy
• Other uses.
The investigation predicts revenues of leading products in the market: Apligraf, Dermagraft, DeNovo NT and Osteocel Plus. Research, data and analyses cover activities of Shire Regenerative Medicine, Advanced Cell Technology, Athersys, Mesoblast, Geron and other companies.
That study discusses R&D and commercial news, shows research interviews and predicts revenues to 2022 in leading regional markets. The work analyses the United States, Europe (EU, Norway, Switzerland and Iceland), Asia Pacific (Japan, China, India and South Korea), and the rest of the world (as a group), including Brazil and Russia.
Translational Regenerative Medicine: Market Prospects 2012-2022 adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For sample pages and further information concerning the Translational Regenerative Medicine: Market Prospects 2012-2022 please visit: http://www.visiongain.com/Report/886/Translational-Regenerative-Medicine-Market-Prospects-2012-2022
For an executive summary of this report or to order it today please contact:
Email: Sara Peerun on email@example.com
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.